Sei Investments Co. Has $4.06 Million Stake in Smith & Nephew SNATS, Inc. $SNN

Sei Investments Co. boosted its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) by 29.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 127,719 shares of the medical equipment provider’s stock after acquiring an additional 28,811 shares during the quarter. Sei Investments Co.’s holdings in Smith & Nephew SNATS were worth $4,059,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in SNN. Royal Bank of Canada increased its stake in shares of Smith & Nephew SNATS by 16.7% during the 1st quarter. Royal Bank of Canada now owns 340,428 shares of the medical equipment provider’s stock worth $9,657,000 after purchasing an additional 48,784 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Smith & Nephew SNATS by 49.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after purchasing an additional 583,809 shares during the last quarter. Focus Partners Wealth grew its holdings in Smith & Nephew SNATS by 59.8% during the first quarter. Focus Partners Wealth now owns 19,438 shares of the medical equipment provider’s stock worth $552,000 after purchasing an additional 7,277 shares during the period. Cetera Investment Advisers grew its holdings in Smith & Nephew SNATS by 5.9% during the second quarter. Cetera Investment Advisers now owns 17,731 shares of the medical equipment provider’s stock worth $543,000 after purchasing an additional 983 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in Smith & Nephew SNATS by 219.2% during the second quarter. EverSource Wealth Advisors LLC now owns 5,261 shares of the medical equipment provider’s stock worth $161,000 after buying an additional 3,613 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Trading Down 1.5%

Smith & Nephew SNATS stock opened at $29.68 on Friday. Smith & Nephew SNATS, Inc. has a 12 month low of $28.56 and a 12 month high of $38.79. The stock’s 50 day moving average is $30.45 and its 200-day moving average is $32.14. The company has a quick ratio of 1.25, a current ratio of 2.14 and a debt-to-equity ratio of 0.62.

Smith & Nephew SNATS Announces Dividend

The company also recently disclosed a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be issued a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on SNN shares. Kepler Capital Markets lowered Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th. Canaccord Genuity Group reduced their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. Sanford C. Bernstein set a $31.85 target price on Smith & Nephew SNATS in a report on Monday, May 11th. Morgan Stanley restated an “overweight” rating on shares of Smith & Nephew SNATS in a research note on Wednesday. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Smith & Nephew SNATS has an average rating of “Hold” and an average target price of $30.93.

Smith & Nephew SNATS Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.